BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL
- Tuesday, June 30, 2020, 7:03
- Finance
- Add a comment
LUND, Sweden, June 30, 2020 /PRNewswire/ — BioInvent International AB (“BioInvent”) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a clinical…
About the Author
adminasapcorp has written 41268 stories on this site.